Foghorn Therapeutics, Inc. (FHTX) News

Foghorn Therapeutics, Inc. (FHTX): $13.98

0.38 (+2.79%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add FHTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 399

in industry

Filter FHTX News Items

FHTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest FHTX News From Around the Web

Below are the latest news stories about Foghorn Therapeutics Inc that investors may wish to consider to help them evaluate FHTX as an investment opportunity.

How Much Upside is Left in Foghorn Therapeutics Inc. (FHTX)? Wall Street Analysts Think 26%

The consensus price target hints at a 25.6% upside potential for Foghorn Therapeutics Inc. (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | January 12, 2022

Foghorn Therapeutics Inc. (FHTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Foghorn Therapeutics Inc. (FHTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Yahoo | January 11, 2022

Foghorn Therapeutics Announces Chief Scientific Officer Succession

CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, announced Steven Bellon, Ph.D., currently Senior Vice President of Drug Discovery, is promoted to Chief Scientific Officer, effective today, January 10, 2022. Carl Decicco, Ph.D., is retiring from his role as Chief Scientific Officer at Fog

Yahoo | January 10, 2022

Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Conference

CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Foghorn will present at the H.C. Wainwright BioConnect Conference which is being held virtually on January 10th through the 13th, 2022. With an initial focus in oncology, Foghorn’s Gene Traffic Control Platform and resu

Yahoo | January 7, 2022

Zacks: Analysts Expect Foghorn Therapeutics Inc. (NASDAQ:FHTX) Will Post Quarterly Sales of $330,000.00

Equities research analysts expect that Foghorn Therapeutics Inc. (NASDAQ:FHTX) will post sales of $330,000.00 for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Foghorn Therapeutics earnings, with the highest sales estimate coming in at $500,000.00 and the lowest estimate coming in at $150,000.00. The firm is scheduled to issue []

Dakota Financial News | December 22, 2021

Zacks: Analysts Anticipate Foghorn Therapeutics Inc. (NASDAQ:FHTX) to Post -$0.29 Earnings Per Share

Analysts expect Foghorn Therapeutics Inc. (NASDAQ:FHTX) to post ($0.29) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Foghorn Therapeutics earnings, with the lowest EPS estimate coming in at ($0.72) and the highest estimate coming in at $0.56. The business is scheduled to report its next []

Dakota Financial News | December 20, 2021

Zacks: Analysts Anticipate Foghorn Therapeutics Inc. (NASDAQ:FHTX) Will Post Quarterly Sales of $330,000.00

Brokerages predict that Foghorn Therapeutics Inc. (NASDAQ:FHTX) will announce $330,000.00 in sales for the current quarter, according to Zacks. Two analysts have issued estimates for Foghorn Therapeutics earnings, with the highest sales estimate coming in at $500,000.00 and the lowest estimate coming in at $150,000.00. The business is expected to announce its next quarterly earnings []

Transcript Daily | December 19, 2021

-$0.29 Earnings Per Share Expected for Foghorn Therapeutics Inc. (NASDAQ:FHTX) This Quarter

Equities analysts predict that Foghorn Therapeutics Inc. (NASDAQ:FHTX) will announce earnings per share of ($0.29) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Foghorn Therapeutics earnings, with the highest EPS estimate coming in at $0.56 and the lowest estimate coming in at ($0.72). The business is expected to []

Dakota Financial News | December 17, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning, trader!

William White on InvestorPlace | December 14, 2021

58 Biggest Movers From Yesterday

Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) shares jumped 80.4% to close at $90.08 on Monday. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-cash transaction. Foghorn Therapeutics Inc. (NASDAQ: FHTX ) shares jumped 55% to close at $18.58. Loxo Oncology, an R&D group of Eli Lilly And Co (NYSE: LLY ), and Foghorn Therapeutics collaborated to create oncology medicines by applying Foghorn''s Gene Traffic Control platform. BELLUS Health Inc. (NASDAQ: BLU ) gained 48.2% to settle at $8.30 after the company announced topline data its Phase 2b SOOTHE trial of BLU-5937 in Refractory Chronic Cough. Petros Pharmaceuticals, Inc. (NASDAQ: PTPI ) surged 47.4% to close at $3.98 after gaining more than 14% on Friday. Energy Focus, Inc. (NASDAQ: EFOI ) gained 36.2% t...

Benzinga | December 14, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.419 seconds.